S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83

Natera Stock Forecast, Price & News

+6.30 (+7.30%)
(As of 12/7/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
1.48 million shs
Average Volume
881,121 shs
Market Capitalization
$8.76 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive NTRA News and Ratings via Email

Sign-up to receive the latest news and ratings for Natera and its competitors with MarketBeat's FREE daily newsletter.

Natera logo

About Natera

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The firm also offers Constellation, a cloud-based software product that allows laboratory customers to gain access to the algorithms and bioinformatics in order to validate and launch tests based on the technology. The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in San Carlos, CA.


Should I Avoid Natera Inc (NTRA)?
December 8, 2021 |  finance.yahoo.com
Natera (NASDAQ:NTRA) Shares Gap Down to $94.66
November 30, 2021 |  americanbankingnews.com
Relative Strength Alert For Natera - Nasdaq
November 29, 2021 |  nasdaq.com
Notable Natera Insider Makes $2.8M Sale
November 15, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Medical laboratories
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$391.01 million
Book Value
$8.02 per share


Net Income
$-229.74 million
Pretax Margin




Free Float
Market Cap
$8.76 billion

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.44 out of 5 stars

Medical Sector

162nd out of 1,394 stocks

Medical Laboratories Industry

3rd out of 30 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -

Natera (NASDAQ:NTRA) Frequently Asked Questions

Is Natera a buy right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Natera in the last twelve months. There are currently 1 hold rating and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Natera stock.
View analyst ratings for Natera
or view top-rated stocks.

How has Natera's stock been impacted by COVID-19?

Natera's stock was trading at $31.02 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NTRA stock has increased by 198.4% and is now trading at $92.56.
View which stocks have been most impacted by COVID-19

When is Natera's next earnings date?

Natera is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Natera

How were Natera's earnings last quarter?

Natera, Inc. (NASDAQ:NTRA) announced its earnings results on Thursday, November, 4th. The medical research company reported ($1.63) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.27) by $0.36. The medical research company earned $158.10 million during the quarter, compared to analysts' expectations of $151.92 million. Natera had a negative net margin of 72.15% and a negative trailing twelve-month return on equity of 85.05%. The business's revenue was up 61.2% on a year-over-year basis. During the same period last year, the business posted ($0.72) earnings per share.
View Natera's earnings history

What guidance has Natera issued on next quarter's earnings?

Natera issued an update on its FY 2021 earnings guidance on Thursday, December, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $615 million-$625 million, compared to the consensus revenue estimate of $614.70 million.

What price target have analysts set for NTRA?

12 brokers have issued 1 year price targets for Natera's shares. Their forecasts range from $129.00 to $160.00. On average, they expect Natera's share price to reach $146.64 in the next twelve months. This suggests a possible upside of 58.4% from the stock's current price.
View analysts' price targets for Natera
or view top-rated stocks among Wall Street analysts.

Who are Natera's key executives?

Natera's management team includes the following people:

What is Steve Chapman's approval rating as Natera's CEO?

158 employees have rated Natera CEO Steve Chapman on Glassdoor.com. Steve Chapman has an approval rating of 91% among Natera's employees. This puts Steve Chapman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Natera own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Natera investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Transocean (RIG) and Allergan (AGN).

When did Natera IPO?

(NTRA) raised $101 million in an initial public offering (IPO) on Thursday, July 2nd 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray served as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.

What is Natera's stock symbol?

Natera trades on the NASDAQ under the ticker symbol "NTRA."

Who are Natera's major shareholders?

Natera's stock is owned by many different retail and institutional investors. Top institutional shareholders include Invesco Ltd. (3.23%), RTW Investments LP (1.97%), Marshall Wace LLP (1.44%), Farallon Capital Management LLC (1.37%), American Century Companies Inc. (1.28%) and Millennium Management LLC (1.26%). Company insiders that own Natera stock include Daniel Rabinowitz, Gail Boxer Marcus, Herm Rosenman, James Healy, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Patrick J Donovan, Robert Alan Schueren, Roelof Botha, Rowan E Chapman, Roy D Baynes, Steven Leonard Chapman, Todd C Cozzens and Todd C Cozzens.
View institutional ownership trends for Natera

Which major investors are selling Natera stock?

NTRA stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Millennium Management LLC, Macquarie Group Ltd., Two Sigma Advisers LP, Balyasny Asset Management LLC, Balyasny Asset Management LLC, Frontier Capital Management Co. LLC, and Kornitzer Capital Management Inc. KS. Company insiders that have sold Natera company stock in the last year include Daniel Rabinowitz, Herm Rosenman, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Robert Alan Schueren, Roelof Botha, Rowan E Chapman, Steven Leonard Chapman, and Todd C Cozzens.
View insider buying and selling activity for Natera
or view top insider-selling stocks.

Which major investors are buying Natera stock?

NTRA stock was bought by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Invesco Ltd., Bamco Inc. NY, Point72 Asset Management L.P., Janus Henderson Group PLC, Suvretta Capital Management LLC, Allianz Asset Management GmbH, and Deutsche Bank AG. Company insiders that have bought Natera stock in the last two years include James Healy, and Patrick J Donovan.
View insider buying and selling activity for Natera
or or view top insider-buying stocks.

How do I buy shares of Natera?

Shares of NTRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Natera's stock price today?

One share of NTRA stock can currently be purchased for approximately $92.56.

How much money does Natera make?

Natera has a market capitalization of $8.76 billion and generates $391.01 million in revenue each year. The medical research company earns $-229.74 million in net income (profit) each year or ($4.58) on an earnings per share basis.

How many employees does Natera have?

Natera employs 1,815 workers across the globe.

What is Natera's official website?

The official website for Natera is www.natera.com.

Where are Natera's headquarters?

How can I contact Natera?

Natera's mailing address is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. The medical research company can be reached via phone at (650) 249-9090 or via email at [email protected].

This page was last updated on 12/8/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.